ArticleHealth science reports2025
Economic Burden of Obesity in Iran University of Medical Sciences: A Cost Analysis Using the Cost of Illness Framework.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Obesity is a multifaceted health issue that significantly elevates the risk of various chronic diseases and can lead to a reduction in life expectancy by 5-20 years. This study aimed to estimate both the direct and indirect costs associated with obesity among the population served by Iran University of Medical Sciences in 2023. Methods: This study employed a cost of illness (COI) framework, utilizing a prevalence-based approach from a societal perspective, specifically targeting the obese demographic. Subsequently, using prevalence and cost data, we calculated the expenses related to each obesity-associated disease, categorizing them into direct medical, direct nonmedical, and indirect costs. The costs for each disease were then adjusted based on the attributable fraction of the obese population, and the total costs associated with obesity-related diseases were aggregated. Results: The economic burden of obesity-attributable to six specific diseases within the population covered by Iran University of Medical Sciences was estimated at approximately $PPP 2452 million, representing 31% of the total economic burden of these six chronic diseases, which amounts to $PPP 7804 million. Of the total economic burden due to obesity, direct medical costs accounted for $PPP 1362 million (56%), direct nonmedical costs were $PPP 76 million (3%), and indirect costs reached $PPP 1014 million (41%). Conclusion: The financial implications of obesity, particularly in relation to certain diseases, are substantial. There is an urgent need for cost-effective preventive measures aimed at controlling and reducing the prevalence of overweight and obesity, thereby mitigating their adverse health impacts and economic consequences.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.